cancer vaccines; grows as an epithelial, adherent monolayer culture; does not overexpress estrogen receptors; overexpresses her2/neu; sensitive in vitro to cyclophosphamide (4HC), etoposide and taxol; resistant in vitro to carboplatin; demonstrates karyotypic abnormalities
Inventors
Wiseman, Charles • Kharazi, Alex
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-7674456-B2
Publication Date
2010-03-09
Expiration Date
Abstract
The invention provides, in part, novel SV-BR cancer cell lines. The invention provides a novel cell line SV-BR-1 deposited under ATCC PTA-1712 and SV-BR-1-GM cells deposited under ATCC PTA-1713. The invention further relates to therapeutic and non-therapeutic uses of the novel cell lines. Therapeutic uses include the use of SV-BR cell lines as cancer vaccines, and in particular, or the treatment of cancer.
Core Innovation
The invention provides novel SV-BR cancer cell lines for use in compositions. The SV-BR cells are defined as growing as an epithelial, adherent monolayer culture and lacking estrogen receptor overexpression while overexpressing her2/neu. The cells further demonstrate in vitro chemosensitivity to cyclophosphamide (4HC), etoposide, and taxol and in vitro resistance to carboplatin.
The disclosed SV-BR cells also demonstrate karyotypic abnormalities and aneuploidy. Specific SV-BR variants are identified, including SV-BR-1 and SV-BR-1-GM deposited at ATCC under accession numbers PTA-1712 and PTA-1713, respectively. The disclosure connects these cellular characteristics to cancer vaccine and tumor treatment contexts.
The invention further encompasses use of SV-BR cells to induce an immune response in a subject, including immune responses such as Th1. Genetic modification of SV-BR cells is described to express polypeptides, including cytokines such as GM-CSF, IFN-α, IL-2, IL-4, IL-12, and related immune-stimulatory components. The document also describes use of irradiated or proliferation-inhibited SV-BR cells.
Claims Coverage
The partial content includes two independent claims. Together, they cover four inventive features centered on defined SV-BR cells and immune response-inducing compositions.
Defined SV-BR cell composition with growth and receptor profile
A composition comprising at least one SV-BR cell that grows as an epithelial, adherent monolayer culture, does not overexpress estrogen receptors, and overexpresses her2/neu, together with a physiologically acceptable carrier.
In vitro chemosensitivity/resistance and genomic abnormality-defined SV-BR cell composition
The composition further includes an SV-BR cell that is sensitive in vitro to cyclophosphamide (4HC), etoposide, and taxol, resistant in vitro to carboplatin, and demonstrates karyotypic abnormalities with aneuploid cell status.
Immune response-inducing composition with defined SV-BR characteristics
A composition for inducing an immune response in a subject in need thereof comprising a physiologically acceptable carrier and at least one SV-BR cell having epithelial adherent monolayer growth, no estrogen receptor overexpression, her2/neu overexpression, in vitro sensitivity to cyclophosphamide (4HC), etoposide, and taxol, and in vitro resistance to carboplatin.
Immune response-inducing SV-BR composition with enumerated karyotypic abnormalities and aneuploidy
The immune response-inducing SV-BR cell is further defined as an aneuploid cell and demonstrates one or more specified karyotypic abnormalities, with karyotypic features listed in the claim text.
Across the independent claims, the inventive subject matter is centered on SV-BR cells defined by epithelial adherent monolayer growth, specified receptor expression, in vitro chemosensitivity/resistance to named agents, karyotypic abnormalities and aneuploidy, and additional enumeration of karyotypic abnormalities in the immune response claim.
Stated Advantages
Induces an immune response in a subject in need thereof.
Documented Applications
Cancer vaccine and tumor treatment applications using SV-BR cell compositions.
Potential use in cancers overexpressing HER2, including breast, ovarian, and lung.
Immune response induction in a subject, including Th1 response.
Cancer vaccine study context in stage IV breast cancer and survival outcomes described in the disclosure.
Interested in licensing this patent?